Q-omics provides the consensus-scored ZNF789 profile across patient tissues and cancer cell-line models. ZNF789 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF789 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ZNF789 RNA expression shows 21,036 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where ZNF789 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF789 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF789 survival associations across molecular data types. ZNF789 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF789 RNA expression–survival associations across cancer types. High ZNF789 expression shows unfavorable associations in ACC, KIRC, KICH, MESO and LIHC, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF789 RNA expression.
This table summarizes ZNF789 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF789. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF789 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, STAD and COAD. The LIHC box plot shows higher ZNF789 RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with ZNF789 in patient tissues and cancer cell lines. In patient samples, ZNF789 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF789 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
